August 2012
-
Aptar CSP Technologies has announced an expansion of its cGMP manufacturing capacity for clinical packaging of dry powder inhalation capsules using the company’s Activ-Blister technology. Aptar CSP cited growing demand for the technology for both… Read more . . .
-
3P innovation has announced that it is now offering new filling technology in its custom-built DPI filling systems that is based on equipment originally patented by GSK for high-speed filling of Diskus dry powder inhalers.… Read more . . .
-
LTR Pharma announced a development agreement with Strategic Drug Solutions, Inc. for development of a nasal spray for the treatment of esophageal motility disorders (difficulty in swallowing). The Australian company says that the product will… Read more . . .
-
Intertek has announced a 6,000 sq ft expansion of its facility in Melbourn, UK to add laboratory space for characterization of large molecules for inhalation. In 2019, the company acquired a facility that doubled its… Read more . . .
-
Vaccine developer Ethris, which recently received $5 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for development of spray-dried RNA vaccines for nasal delivery, has announced that EU4Health has awarded the company… Read more . . .
-
According to AstraZeneca, the Phase 3 KALOS and LOGOS trials comparing Breztri (Trixeo) Aerosphere budesonide / glycopyrronium / formoterol fumarate MDI to inhaled ICS/LABA in patients with uncontrolled asthma both met their primary endpoints. Breztri… Read more . . .
-
Ritedose Pharmaceuticals has announced that the FDA approved the transfer of an ANDA for formoterol fumarate inhalation solution to Ritedose in April 2025. The company says that it expects to start shipping formoterol fumarate inhalation solution… Read more . . .
-
According to Satsuma Pharmaceuticals, the FDA has approved the company’s NDA for Atzumi dihydroergotamine nasal powder (STS101) for the treatment of migraine in adults. Although the Phase 3 SUMMIT trial of STS101 failed to meet its… Read more . . .
-
Inhalation CDMO Bespak announced that it has completed an independently verified life cycle assessment to evaluate environmental impacts associated with materials and manufacturing of its BK357 metered dose inhaler valve. The company said that the assessment… Read more . . .
-
Nocion Therapeutics, which is developing inhaled dry powder taplucainium (NOC-110, formerly NTX-1175) for the treatment of chronic cough, has announced the appointment of Matthew Frankel as Chief Medical Officer. Frankel was most recently Chief Medical… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.